BOUL.ST
Latest Trade
78.80SEKChange
5.10(+6.92%)Volume
58,551Today's Range
-
79.6052 Week Range
-
79.60As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 73.70 |
|---|---|
Open | 73.70 |
Volume | 58,551 |
3M AVG Volume | 0.36 |
Today's High | 79.60 |
Today's Low | 73.00 |
52 Week High | 79.60 |
52 Week Low | 37.45 |
Shares Out (MIL) | 19.42 |
Market Cap (MIL) | 1,530.02 |
Forward P/E | -- |
Dividend (Yield %) | 0.76 |
Boule Diagnostics Q4 Operating Profit Rises To SEK 15.1 Mln
Boule Diagnostics Names Christina Rubenhag Interim CEO
Boule Diagnostics Appoints Jesper Soderqvist CEO
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Company’s product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Company’s primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
Executive Leadership
Peter von Ehrenheim
Independent Chairman of the Board
Christina Rubenhag
Acting President and Chief Executive Officer, Chief Financial Officer, Senior Vice President
Fredrik Dalborg
President, Chief Executive Officer
Fredrik Ekdahl
Senior Vice President Research & Development
Michael Elliott
Senior Vice President Research & Development at CDS
Price To Earnings (TTM) | 40.71 |
|---|---|
Price To Sales (TTM) | 3.07 |
Price To Book (MRQ) | 4.60 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 46.08 |
LT Debt To Equity (MRQ) | 18.20 |
Return on Investment (TTM) | 10.03 |
Return on Equity (TTM) | 6.89 |
* Q4 NET SALES SEK 129.3 MILLION VERSUS SEK 106.2 MILLION YEAR AGO
* JESPER SÖDERQVIST TAKES OFFICE MAY 11, 2020 AT THE LATEST Source text for Eikon:
* SAID ON FRIDAY UNIT BOULE MEDICAL RECEIVED A WARNING LETTER FROM THE US FOOD AND DRUG ADMINISTRATION
* UNIT BOULE MEDICAL AB BUYS NEW TECHNOLOGIES FROM DREW SCIENTIFIC, INC.
* Q4 NET SALES SEK 107.2 MILLION VERSUS SEK 104.6 MILLION YEAR AGO
* Q3 NET SALES SEK 109.7 MILLION VERSUS SEK 108.5 MILLION YEAR AGO
* CHRISTINA RUBENHAG NEW CFO FROM OCT.9 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* Q2 NET SALES SEK 104.3 MILLION VERSUS SEK 102.0 MILLION YEAR AGO
* BOULE DIAGNOSTICS OPTIMIZES MANUFACTURING STRUCTURE - CLOSES FACTORY IN CHINA
* Q1 NET SALES SEK 106.6 MILLION VERSUS SEK 84.4 MILLION YEAR AGO
* Installation of instruments will begin in Q2 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* Q4 net sales 105.8 million Swedish crowns ($11.89 million) versus 88.4 million crowns year ago
* Q4 net sales 105.8 million Swedish crowns ($12 million)versus 88.4 million crowns year ago
* Said on Wednesday had revised its financial targets and adjusted dividend policy
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.